### CMB International Securities | Equity Research | Company Update



招商银行全资附属机模 A Wholly Owned Subsidiary Of China Merchants Bank

# Bosideng (3998 HK)

### The negatives should have been priced in

After recent share price retreat (declined by 26% since Dec), we believe the negatives (e.g. warm weather in Dec and Jan, COVID-19 outbreaks) should mostly be priced in. Also, even though Canada Goose result was a miss, its performance in China was not disappointing, hence giving us more confidence on Bosideng's sales trend. The valuation of the stock is not demanding at 15x FY23E P/E, vs 5-year average of 17x. Maintain BUY but fine-tuned TP to HK\$ 5.31.

- Canada Goose's 3Q22 result missed but China sales was resilient, hence positive to Bosideng. Canada Goose reported its 3Q22 results. Sales grew by 24% YoY, inline with BBG est., while net profit was up 42%, missed BBG est. by 16%. Management also revised down its FY22E sales/ net profit guidance by 5%/ 14% to CAD ~11.0bn/ ~170mn and attributed this cut to new COVID-19 outbreaks in APAC and EMEA. More importantly, Canada Goose's China DTC sales growth had slowed down to 35% in 3Q22 (ending Dec 2021), from 86% in the last quarter, but we still think that was a decent number, esp. when online sales can still grow by 60%.
- We believe Bosideng's sales was soft during Dec and Jan. We believe Bosideng's sales growth should have slowed down in Dec 2021 and Jan 2022 (vs Nov 2021), where Canada Goose had a similar observation, perhaps due to warmer weather (1.5/1.7 degrees hotter than last year during Dec/ Jan in BJ, SH and SZ on average) and slower economic growth. Moreover, ASP increases should also be less than expected, together with a widened level of retail discounts. Hence, we revised down Bosideng's down apparel sales growth to 11% (from 21%) in 2H22E (slower than 16% in 1H22) with a lower GP margin.
- However, an improving Feb 2022 and recent price retreat should have priced in the negatives. According to our research, Bosideng's sales growth should have accelerated since Feb 2022, thanks to better weather and more promotions, which is cheerful as it is presumably facing a higher base (due to early CNY this year). Together with the share price retreat of 26% since Dec 2021, it is not that demanding.
- Maintain BUY but cut TP to HK\$ 5.31. We revised down our diluted EPS by 10%/ 9%/ 9% in FY22E/ 23E/ 24E to factor in slower sales growth and lower GP margin. Reiterate BUY but cut TP to HK\$ 5.31, based on 20x FY23E P/E (revised down from 23x, to factor in de-rating). Current valuation of 15x FY23E P/E with a 21% FY21-24E NP CAGR is undemanding, vs 5 years average of 17x and GOOS's 21x, MONC's 30x and Li Ning's 36x.

### **Earnings Summary**

Lammigo Gammary					
(YE 31 Mar)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	12,191	13,517	15,094	17,202	19,291
YoY growth (%)	17.4	10.9	11.7	14.0	12.1
Net income (RMB mn)	1,203	1,710	2,026	2,486	3,010
Diluted EPS (RMB)	0.111	0.151	0.180	0.220	0.267
YoY growth (%)	12.8	48.1	20.7	22.7	21.1
Consensus EPS (RMB)	n/a	n/a	0.215	0.256	0.301
P/E (x)	33.4	22.5	18.7	15.2	12.6
P/B (x)	3.8	3.3	3.0	2.8	2.5
Yield (%)	2.2	3.3	3.7	4.6	5.6
ROE (%)	12.0	16.1	17.7	20.1	22.2
Net gearing (%)	Net cash	1.8	2.5	Net cash	Net cash

Source: Company data, Bloomberg, CMBIS estimates

### **BUY (Maintain)**

Target Price HK\$5.31
(Previous TP HK\$6.69)
Up/Downside +31.4%
Current Price HK\$4.04

#### **China Apparel Sector**

Walter Woo (852) 3761 6974 walterwoo@cmbi.com.hk

Stock Data	
Mkt Cap (HK\$ mn)	43,972
Avg 3 mths t/o (HK\$ mn)	139.91
52w High/Low (HK\$)	6.93/2.99
Total Issued Shares (mn)	10,884.2
Source: Bloomberg	

Shareholding Structure	
Mr Gao Dekang & Family	70.49%
Employee incentive scheme	6.81%
Free Float	22.70%
Source: HKEx	

Share Perform	iance	
	Absolute	Relative
1-mth	-8.5%	-10.3%
3-mth	-33.0%	-31.9%
6-mth	-33.7%	-29.8%
12-mth	6.0%	28.4%
Source: Bloombe	rg	



Source: Bloomberg

Auditor: KPMG

#### **Related Reports**

- Bosideng (3998 HK, BUY) Bosideng and BOGNER to codevelop the Greater China market – 3 Dec 2021
- Bosideng (3998 HK, BUY) Successful new product and premiumization – 29 Nov 2021
- Bosideng (3998 HK, BUY)
   Outstanding double 11 and e
   commerce sales 15 Nov 2021



# **Earnings revision**

Figure 1: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	15,094	17,202	19,291	15,904	18,137	20,352	-5.1%	-5.2%	-5.2%
Gross profit	9,060	10,511	11,918	9,694	11,128	12,623	-6.5%	-5.5%	-5.6%
EBIT	2,716	3,303	3,933	3,024	3,612	4,292	-10.2%	-8.6%	-8.3%
Net profit att.	2,026	2,486	3,010	2,261	2,726	3,290	-10.4%	-8.8%	-8.5%
Diluted EPS (RMB)	0.180	0.220	0.267	0.200	0.241	0.291	-10.4%	-8.8%	-8.5%
Gross margin	60.0%	61.1%	61.8%	61.0%	61.4%	62.0%	-0.9ppt	-0.3ppt	-0.2ppt
EBIT margin	18.0%	19.2%	20.4%	19.0%	19.9%	21.1%	-1ppt	-0.7ppt	-0.7ppt
Net profit att. margin	13.4%	14.5%	15.6%	14.2%	15.0%	16.2%	-0.8ppt	-0.6ppt	-0.6ppt

Source: Company data, CMBIS estimates

Figure 2: CMBIS estimates vs consensus


		CMBIS			Consensus		Diff (%)			
RMB mn	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	
Revenue	15,094	17,202	19,291	16,164	19,190	22,466	-6.6%	-10.4%	-14.1%	
Gross profit	9,060	10,511	11,918	9,751	11,722	13,870	-7.1%	-10.3%	-14.1%	
EBIT	2,716	3,303	3,933	2,869	3,549	4,264	-5.3%	-6.9%	-7.8%	
Net profit att.	2,026	2,486	3,010	2,189	2,691	3,287	-7.4%	-7.6%	-8.4%	
Diluted EPS (RMB)	0.180	0.220	0.267	0.215	0.256	0.301	-16.4%	-13.9%	-11.5%	
Gross margin	60.0%	61.1%	61.8%	60.3%	61.1%	61.7%	-0.3ppt	0ppt	0ppt	
EBIT margin	18.0%	19.2%	20.4%	17.8%	18.5%	19.0%	0.2ppt	0.7ppt	1.4ppt	
Net profit att. margin	13.4%	14.5%	15.6%	13.5%	14.0%	14.6%	-0.1ppt	0.4ppt	1ppt	

Source: Company data, CMBIS estimates




### **Focus Charts**

Figure 3: Canada Goose's sales growth by region




Source: Company data, CMBIS estimates

Figure 4: Canada goose Asia and Bosideng's sales growth



Source: Company data, CMBIS estimates

Figure 5: Temperature in Beijing, Shanghai and Shenzhen in 2021 Winter vs last year



Source: Bloomberg, CMBIS estimates



## **Assumption**

Figure 6: CMBIS estimates vs consensus

Major assumptions	FY20A	FY21A	FY22E	FY23E	FY24E
Sales by segment (RMB mn)					
Down apparels	9,513	10,889	12,242	14,203	16,149
DEM management	1,611	1,536	1,705	1,790	1,880
_adieswear	983	947	966	1,018	1,06
Diversified apparels	84	145	181	190	199
Total	12,191	13,517	15,094	17,202	19,29
Sales by segment growth (%)					
Down apparels	24.2%	14.5%	12.4%	16.0%	13.7%
DEM management	17.8%	-4.7%	11.0%	5.0%	5.0%
_adieswear	-17.7%	-3.7%	2.0%	5.4%	4.4%
Diversified apparels	-48.9%	72.6%	25.0%	5.0%	5.0%
Fotal	17.4%	10.9%	11.7%	14.0%	12.1%
Sales by channel growth (%)					
Down Apparels - offline	23.1%	2.1%	1.3%	7.2%	5.09
Down Apparels - online	28.0%	54.3%	36.0%	30.0%	25.09
DEM management	17.8%	-4.7%	11.0%	5.0%	5.0%
Non-down apparels - offline	-22.3%	1.1%	5.1%	4.6%	4.5%
Non-down apparels - online	-6.1%	21.8%	5.0%	15.0%	5.09
Total	17.4%	10.9%	11.7%	14.0%	12.19
Sales network by segment					
Down apparel	4,866	4,150	4,060	4,170	4,28
Non - down apparel	525	477	469	483	49
Fotal	5,391	4,627	4,528	4,653	4,78
Sales network by channel type					
Self-operated	2,267	2,161	2,154	2,228	2,30
Γhird party distributors	3,131	2,466	2,374	2,425	2,47
Total	5,398	4,627	4,528	4,653	4,78
GP margins by segment					
Down apparels	59.8%	63.7%	66.0%	67.3%	67.79
DEM management	18.5%	19.6%	19.0%	17.0%	17.09
_adieswear	74.4%	72.6%	67.0%	63.0%	63.09
Diversified apparels	-16.4%	0.1%	2.0%	2.0%	2.09
Fotal	55.0%	58.6%	60.0%	61.1%	61.89
Opex breakdown					
D&A/ sales	2.8%	3.6%	2.8%	2.6%	2.39
Rental/sales	11.6%	13.3%	12.9%	13.0%	13.19
_abor/ sales	10.7%	11.9%	11.7%	10.9%	10.79
A&P/ sales	7.0%	6.5%	7.5%	8.0%	8.09
Others/ sales	9.9%	7.7%	8.1%	8.3%	8.19
OP margins	13.1%	16.5%	18.0%	19.2%	20.49
Effective tax rate	25.3%	24.0%	25.0%	25.0%	25.0%
NP att. margins	9.9%	12.6%	13.4%	14.5%	15.6%
NP att. growth (%)	22.6%	42.1%	18.5%	22.7%	21.1%

Source: Company data, CMBIS estimates



### **Valuation**

Figure 7: Peers' valuation

			12m TP	Price	Up/ Down-	Mkt. Cap	Year	P/E	(x)	P/B	(x)	ROE (%)	3yrs PEG (x)	Yield (%)
Company	Ticker	Rating	(LC)	(LC)	side	(HK\$mn)	End	FY1E	FY2E	FY1E	FY2E	FY1E	FY1E	FY1E
H-shares Apparel														
Bosideng Intl	3998 HK	BUY	5.31	4.04	31%	43,972	Mar-21	18.7	15.2	3.0	2.8	17.5	0.9	4.4
China Lilang	1234 HK	BUY	6.27	4.45	41%	5,329	Dec-20	6.3	5.4	1.1	1.0	15.6	0.3	10.8
Jnby Design	3306 HK	BUY	22.84	11.16	105%	5,789	Jun-21	6.8	5.9	2.6	2.3	40.4	1.1	10.3
Cosmo Lady	2298 HK	NR	n/a	0.50	n/a	1,125	Dec-20	n/a	8.7	0.4	0.4	1.2	0.0	1.5
Mulsanne Group	709 HK	NR	n/a	1.64	n/a	2,589	Dec-20	14.9	11.7	n/a	n/a	5.2	(0.1)	n/a
Giordano	1817 HK	NR	n/a	4.45	n/a	4,228	Dec-20	n/a	n/a	n/a	n/a	(13.6)	0.0	n/a
Koradior	3709 HK	NR	n/a	12.48	n/a	8,787	Dec-20	11.4	9.2	1.8	1.6	17.2	0.4	4.3
							Avg.	11.6	9.3	1.8	1.6	11.9	0.4	6.3
							Med.	11.4	8.9	1.8	1.6	15.6	0.3	4.4
A-shares Apparel														
Ningbo Peacebird	603877 CH	NR	n/a	24.38	n/a	14,258	Dec-20	12.8	10.5	2.6	2.3	25.1	0.5	4.
Joeone Co Ltd	601566 CH	NR	n/a	12.02	n/a	8,473	Dec-20	29.1	19.2	1.7	1.6	3.6	6.0	3.
Fujian Septwolves	002029 CH	NR	n/a	5.89	n/a	5,460	Dec-20	17.8	13.6	0.7	0.7	4.1	0.8	2.
Hla Corp Ltd	600398 CH	NR	n/a	6.20	n/a	32,855	Dec-20	9.4	8.0	1.7	1.5	18.2	0.3	7
Jiangsu Hongdou	600400 CH	NR	n/a	3.29	n/a	9,248	Dec-20	62.1	49.1	2.2	2.2	2.7	4.2	n
Dazzle Fashion	603587 CH	NR	n/a	18.03	n/a	10,643	Dec-20	11.9	10.2	2.3	2.1	20.4	0.6	5
Anzheng Fashion	603839 CH	NR	n/a	8.95	n/a	4,393	Dec-20	16.9	15.4	n/a	n/a	6.7	1.7	n,
Lancy Co Ltd	002612 CH	NR	n/a	26.15	n/a	14,194	Dec-20	46.9	33.2	3.7	3.3	8.4	0.9	n/
Shenzhen Huijie	002763 CH	NR	n/a	9.35	n/a	4,703	Dec-20	n/a	n/a	n/a	n/a	15.7	0.0	n/
Ellassay Fashion	603808 CH	NR	n/a	12.62	n/a	5,714	Dec-20	12.8	10.8	1.6	1.5	14.0	2.5	3
Bobaolon Co	002776 CH	NR	n/a	2.63	n/a	1,736	Dec-20	n/a	n/a	n/a	n/a	(22.0)	0.0	n,
							Avg.	24.4	18.9	2.1	1.9	8.8	1.6	4.
							Med.	16.9	13.6	1.9	1.8	8.4	0.8	3.
International Appa	rel													
Canada Goose	GOOS US	NR	n/a	26.90	n/a	22,386	Mar-21	31.9	21.0	7.4	5.5	19.0	0.0	n/a
Moncler Spa	MONC IM	NR	n/a	53.40	n/a	128,912	Dec-20	36.5	29.6	6.3	5.6	22.3	1.8	1.1
Hugo Boss	BOSS GR	NR	n/a	55.42	n/a	34,415	Dec-20	30.2	21.1	4.3	3.7	6.3	(0.2)	1.5
Ted Baker	TED LN	NR	n/a	87.60	n/a	1,705	Jan-21	n/a	17.9	n/a	n/a	(21.7)	0.0	0.0
Next	NXT LN	NR	n/a	7180.0	n/a	100,134	Jan-21	13.7	12.9	9.7	7.9	88.3	0.3	3.4
Hennes & Mauritz	HMB SS	NR	n/a	176.96	n/a	242,396	Nov-21	19.3	16.8	4.7	4.4	19.2	1.1	4.6
Industria De Diseno	ITX SM	NR	n/a	24.98	n/a	686,727	Jan-21	21.4	18.9	4.9	4.6	20.2	0.4	4.0
Ovs Spa	OVS IM	NR	n/a	2.29	n/a	5,887	Jan-21	11.9	9.7	0.7	0.7	16.9	0.5	0.0
Pvh Corp	PVH US	NR	n/a	98.13	n/a	53,569	Jan-21	10.5	9.7	1.4	1.2	10.2	(0.1)	0.1
Vf Corp	VFC US	NR	n/a	60.74	n/a	184,277	Apr-21	19.0	16.7	6.6	6.4	41.1	0.3	3.2
Marks & Spencer	MKS LN	NR	n/a	193.50	n/a	39,964	Apr-21	9.1	10.3	1.5	1.4	1.1	(0.0)	0.3
-							Avg.	20.3	16.8	4.7	4.2	20.3	0.4	1.8
							Med.	19.1	16.8	4.8	4.5	19.0	0.3	1.3

Source: Bloomberg, CMBIS estimates



# **Financial Summary**

Income statement						Cash flow summary					
YE 31 Mar (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Mar (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	12,191	13,517	15,094	17,202	19,291	EBIT	1,599	2,225	2,716	3,303	3,933
Down apparels	9,513	10,889	12,242	14,203	16,149	D & A	400	564	356	372	367
OEM management	1,611	1,536	1,705	1,790	1,880	Change in working capital	(487)	425	(752)	(173)	(176)
Ladieswear	983	947	966	1,018	1,063	Income tax paid	(497)	(348)	(678)	(832)	(1,007)
Diversified apparels	84	145	181	190	199	Others	218	267	183	210	280
Cost of goods sold	(5,482)	(5,592)	(6,034)	(6,691)	(7,373)	Net cash from operating	1,233	3,133	1,825	2,881	3,398
Gross profit	6,709	7,924	9,060	10,511	11,918						
Other income	187	204	196	206	212	Capex & investments	(714)	(437)	(488)	(556)	(623)
						Associated companies	1,118	(3,193)	-	-	-
Operating expenses	(5,297)	(5,903)	(6,540)	(7,414)	(8,197)	Interest received	129	153	-	-	-
D & A	(151)	(177)	(148)	(150)	(149)	Others	79	(386)	-	-	-
Staff costs	(1,365)	(1,633)	(1,783)	(1,888)	(2,078)	Net cash from investing	612	(3,863)	(488)	(556)	(623)
S & D costs (ex-staff, D&A)	(2,957)	(3,155)	(3,600)	(4,206)	(4,650)						
Admin exp. (ex-staff, D&A)	(404)	(523)	(555)	(634)	(705)	Equity raised	-	-	-	-	-
Other operating expenses	(419)	(416)	(453)	(536)	(614)	Net change in bank loans	(552)	148	-	-	-
EBIT	1,599	2,225	2,716	3,303	3,933	Dividend paid	(863)	(880)	(1,248)	(1,426)	(1,745)
						Others	1,408	(361)	(187)	(187)	(187)
Finance costs, net	1	18	(4)	23	93	Net cash from financing	(8)	(1,092)	(1,435)	(1,613)	(1,932)
JVs & associates	-	-	-	-	-						
Exceptional	-	-	-	-	-	Net change in cash	1,837	(1,822)	(98)	713	842
Pre-tax profit	1,600	2,242	2,712	3,326	4,026	Beginning cash balance	1,754	3,639	1,771	1,673	2,386
						Exchange difference	47	(46)	-	-	-
Income tax	(405)	(537)	(678)	(832)	(1,007)	Cash at the end of the year	3,639	1,771	1,673	2,386	3,228
Less: Minority interests	(8)	(5)	8	9	10						
Net profit	1,203	1,710	2,026	2,486	3,010						

Balance sheet						Key ratios					
YE 31 Mar (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23
Non-current assets	4,909	6,080	6,211	6,394	6,650	Sales mix (%)					
Fixed asset	1,390	1,762	2,006	2,302	2,671	Down apparels	78.0	80.6	81.1	82.6	83.
Intangible assets & goodwill	1,654	1,572	1,459	1,346	1,234	OEM management	13.2	11.4	11.3	10.4	9.
Prepaid lease payments	99	912	912	912	912	Ladieswear	8.1	7.0	6.4	5.9	5.
Interest in joint ventures	-	-	-	-	-	Diversified apparels	0.7	1.1	1.2	1.1	1.
Other non-current assets	1,765	1,833	1,833	1,833	1,833	Total	100.0	100.0	100.0	100.0	100.
Current assets	12,470	12,877	13,226	14,568	16,049	P&L ratios (%)					
Cash and cash equivalents	3,639	1,771	1,673	2,386	3,228	Gross margin	55.0	58.6	60.0	61.1	61.8
Inventories	2,726	2,646	2,855	3,166	3,488	Operating margin	13.1	16.5	18.0	19.2	20.4
Trade and other receivables	1,197	876	978	1,115	1,250	Pre-tax margin	13.1	16.6	18.0	19.3	20.9
Prepayments	971	1,168	1,305	1,487	1,667	Net margin	9.9	12.6	13.4	14.5	15.0
Other current assets	3,937	6,415	6,415	6,415	6,415	Effective tax rate	25.3	24.0	25.0	25.0	25.0
Current liabilities	4,690	5,442	5,138	5,594	6,057	Balance sheet ratios					
Bank loans	818	671	671	671	671	Current ratio (x)	2.7	2.4	2.6	2.6	2.6
Trade payables	1,830	2,469	1,984	2,200	2,424	Quick ratio (x)	2.1	1.9	2.0	2.0	2.
Accruals & other payables	1,412	1,543	1,724	1,964	2,203	Cash ratio (x)	0.8	0.3	0.3	0.4	0.
Tax payables	365	520	520	520	520	Inventory turnover days	181	173	173	173	173
others	266	239	239	239	239	Trade receivables days	36	24	24	24	2
						Trade payables days	122	161	120	120	120
Non-current liabilities	2,286	2,263	2,263	2,263	2,263	Total debt / total equity ratio (%)	24	21	19	18	. 10
Bank loans	-	-	-	-	-	Net debt / equity ratio (%)	Net cash	2	2	Net cash	Net casi
Deferred income	-	-	-	-	-	Returns (%)					
Deferred tax	140	174	174	174	174	ROE	11.8	15.4	17.1	19.3	21.2
Others	2,146	2,089	2,089	2,089	2,089	ROA	6.9	9.0	10.4	11.9	13.3
						Per share					
Minority Interest	189	182	189	198	207	Diluted EPS (RMB)	0.11	0.15	0.18	0.22	0.27
Total net assets	10,214	11,069	11,847	12,907	14,172	DPS (RMB)	0.08	0.11	0.13	0.15	0.19
Shareholders' equity	10,214	11,069	11,847	12,907	14,172	BVPS (RMB)	0.96	1.03	1.11	1.20	1.32



### **Disclosures & Disclaimers**

### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **CMBIS Ratings**

BUY
Stock with potential return of over 15% over next 12 months
Control Stock with potential return of +15% to -10% over next 12 months
Control Stock with potential loss of over 10% over next 12 months
Control Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.